Glenmark Pharmaceuticals has received manufacturing and marketing approval from India’s drug regulator to launch the oral antiviral drug favipiravir for the treatment of mild to moderate COVID-19 patients in India, the company said in a statement on Friday. “It is for restricted emergency use in India,” Glenmark Pharmaceuticals added.